California Workers’ Rights Update: Key Protections for Low-Wage Workers (July 2026)

California Workers’ Rights Update: Key Protections for Low-Wage Workers (July 2026)

California continues to strengthen labor protections, especially for workers in agriculture, warehousing, and construction. Here’s a concise roundup of recent developments, enforcement actions, and resources drawn from official and advocacy sources.

Wage Updates & Enforcement

Minimum Wage: As of January 1, 2026, California’s statewide minimum wage is $16.90/hour for all employers. Many cities have higher local rates (e.g., Los Angeles ~$18.42). Fast-food workers remain at $20/hour.
Farmworker Wins: The Labor Commissioner recovered over $6 million for farmworkers denied paid sick leave and other protections (Feb 2026). Ongoing federal litigation (supported by CA AG Bonta and UFW) challenges DOL rules that could slash H-2A and domestic farmworker wages.
Wage Theft Crackdowns: Significant citations in construction (e.g., $2.3M against LA developers) and other sectors highlight aggressive enforcement against misclassification and unpaid wages.

Tip: Track all hours worked. Agriculture overtime (phased in) generally applies after 8 hours/day or 40/week for larger employers.

Heat & Safety Protections

Summer heat remains a major hazard in agriculture and construction. Cal/OSHA enforces outdoor rules (triggers at 80°F: water, shade, rest breaks) and indoor standards (82°F). Recent trainings emphasize prevention, especially for nighttime operations and wildfire smoke.

Tip for Workers: Know symptoms of heat illness. Request breaks as needed—retaliation is illegal. Employers must have a written Heat Illness Prevention Plan.

New 2026 Requirements

Know Your Rights Notice (SB 294): Employers must provide an annual stand-alone notice (template from Labor Commissioner) on rights including wage protections, anti-retaliation, and more. Deadline for current employees was Feb 1, 2026.
Enhanced coordination on child labor in agriculture and emergency contact designations.

Resources for Low-Wage Workers

File Claims: Contact the Labor Commissioner’s Office (dir.ca.gov/dlse) for wage claims, retaliation, or violations. Report safety issues to Cal/OSHA.
Advocacy & Legal Aid:
- CRLA.org / California Rural Legal Assistance: Free help for farmworkers on wages, safety, housing.
- LegalAidAtWork.org: Workers’ Rights Clinics (multiple locations, multilingual) for wage theft, discrimination, etc. Helplines: 415-864-8848 or local numbers.
- UFWFoundation.org: Support for farmworkers.
DIR lists community organizations serving agricultural workers.

Stay Informed & Act: Document everything. Wage theft and retaliation complaints are protected. For the latest, visit dir.ca.gov, labor.ca.gov, or calcivilrights.ca.gov. Share this with coworkers—knowledge is power in low-wage industries.

This is a summary for informational purposes. Consult official sources or legal aid for personalized advice.

Celcuity Inc. (CELC): Biotech Rocket Fueled by FDA Priority Review

Executive Summary

Ticker: CELC
Sector: Biotechnology – Oncology
6-Month Performance: +677%
Current Price: ~$107 (52-week range: $7.57 – $96.07)
Market Cap: ~$5 billion
PDUFA Date: July 17, 2026

Celcuity Inc. has delivered one of the most explosive biotech runs in recent memory, surging +677% in just six months as its lead drug candidate gedatolisib advances toward potential FDA approval. With Priority Review granted and a July 17, 2026 PDUFA date set, CELC represents the purest binary catalyst in biotech—a company with zero revenue that could transform into a multi-billion-dollar commercial-stage firm if the FDA says “yes” in five months.

This is high-risk, high-reward biotech at its finest.

The Catalyst: FDA Priority Review + July PDUFA Date

NDA Acceptance (January 20, 2026)

The FDA accepted Celcuity’s New Drug Application (NDA) for gedatolisib and granted Priority Review, setting a PDUFA goal date of July 17, 2026.

What This Means:

Priority Review: 6-month review timeline (vs. standard 10 months)
PDUFA Date: FDA target decision date—approval/rejection by mid-July
RTOR Program: Submitted under Real-Time Oncology Review, designed to facilitate shorter regulatory periods
Prior Designations: Gedatolisib previously received Breakthrough Therapy and Fast Track designations

When the FDA grants Breakthrough Therapy designation, it signals they view the drug as a potential game-changer. When they grant Priority Review, it means they’re prioritizing the application. When they assign a specific PDUFA date, the countdown clock starts ticking.

Timeline:

November 17, 2025: NDA submitted
January 20, 2026: NDA accepted, Priority Review granted
July 17, 2026: PDUFA goal date (FDA decision deadline)

The Drug: Gedatolisib for HR+/HER2- Breast Cancer

What Is Gedatolisib?

Gedatolisib is an investigational multi-target PI3K/AKT/mTOR (PAM) inhibitor that targets:

All four Class I PI3K isoforms (alpha, beta, delta, gamma)
mTORC1 (mechanistic target of rapamycin complex 1)
mTORC2 (mechanistic target of rapamycin complex 2)

Why This Matters:

The PI3K/AKT/mTOR pathway is one of the most commonly dysregulated pathways in cancer. When this pathway goes haywire, cancer cells grow uncontrollably. Blocking it should stop tumor growth.

Previous attempts to inhibit this pathway failed due to toxicity. Single-target inhibitors (like alpelisib, which targets only PI3K alpha) work but cause severe side effects. Pan-PI3K inhibitors (hitting all four isoforms) were even more toxic.

Gedatolisib’s innovation: It hits all four PI3K isoforms AND both mTOR complexes, providing comprehensive pathway blockade, but with a potent pharmacokinetic profile that allows dosing only 3x per month instead of daily. This reduces peak drug concentrations, which dramatically improves tolerability.

CEO Brian Sullivan noted physicians have said some patients “didn’t feel like they were on a cancer drug”—a remarkable statement in oncology.

The Clinical Data: VIKTORIA-1 Phase 3 Trial

PIK3CA Wild-Type Cohort (Basis for NDA)

The NDA is based on data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial:

Study Design:

Population: Patients with HR+/HER2- advanced breast cancer who had received prior CDK4/6 inhibitor therapy (second-line treatment)
Arms:
Gedatolisib triplet: gedatolisib + fulvestrant + palbociclib
Gedatolisib doublet: gedatolisib + fulvestrant
Control: fulvestrant alone

Results:

Treatment Arm	Median PFS	PFS Benefit vs. Control	Hazard Ratio (HR)
Gedatolisib Triplet	9.3 months	+7.3 months	0.24 (76% reduction in disease progression)
Gedatolisib Doublet	7.4 months	+5.4 months	0.33 (67% reduction in disease progression)
Control (Fulvestrant)	2.0 months	—	—

Translation: Patients on gedatolisib triplet had a 76% lower risk of disease progression or death compared to fulvestrant alone. They lived 7.3 months longer without their cancer worsening.

For context, a HR of 0.24 is exceptional in oncology. Most phase 3 trials in this setting show HRs of 0.50-0.70. Gedatolisib’s HR of 0.24 is among the best ever reported for second-line endocrine therapy in HR+/HER2- advanced breast cancer.

The Market Opportunity: $6+ Billion TAM

Second-Line Treatment Landscape

Patient Population:

HR+/HER2- breast cancer represents ~70% of all breast cancer cases
Advanced breast cancer patients who progress after first-line CDK4/6 inhibitor therapy face limited options
Current second-line therapies (fulvestrant, alpelisib + fulvestrant) have modest efficacy and significant toxicity

Celcuity’s Market Estimates:

Eligible patients: ~37,000 women annually (U.S. second-line setting)
Average treatment duration: ~10 months
Pricing: Comparable to current therapies (~$15,000-20,000/month)
Total Addressable Market (TAM): >$6 billion in second-line alone

At 30% market penetration: >$2 billion in annual revenue
Peak sales potential (if successful in first-line too): Could exceed $4-5 billion

CEO Sullivan used Truqap (alpelisib) as a benchmark and noted gedatolisib’s broader patient population (wild-type + mutant) could capture a larger market.

Upcoming Catalysts: Binary Events Ahead

1. PIK3CA Mutant Cohort Data (Q1 or Q2 2026)

The VIKTORIA-1 trial has a second cohort enrolling patients with PIK3CA mutations (a different genetic subset). This cohort compares:

Gedatolisib + fulvestrant
vs. Alpelisib + fulvestrant (current standard of care)

Expected Timing: Late Q1 2026 or Q2 2026 (enrollment complete; awaiting events)

Why This Matters:
Having data in both PIK3CA wild-type AND mutant populations before launch gives physicians a “full data set” to evaluate the drug. If gedatolisib shows superiority in mutants too, the addressable market doubles.

Risk: If the mutant cohort underperforms vs. alpelisib, it limits the market to wild-type only (still valuable, but smaller).

2. FDA PDUFA Date (July 17, 2026)

This is the binary catalyst that will determine CELC’s fate:

Potential Outcomes:

Approval: Stock likely rockets higher; Celcuity transitions to commercial-stage biotech
Complete Response Letter (CRL): Stock crashes; FDA requests additional data/trials
Delayed Decision: Rare, but possible if FDA needs more time

Launch Timeline:
If approved, CEO Sullivan stated Celcuity would launch “soon after” approval. Commercial team is already hired; sales reps are being onboarded now. They’re ready to go.

Commercial Readiness: Building the Infrastructure

Sales Force Buildout

Celcuity began commercial preparation in Q1 2024 with the hiring of a Chief Commercial Officer. Since then, they’ve built out:

2024:

Senior commercial leadership team
Marketing strategy and brand positioning
Key account management structure

2025:

Expansion across medical affairs, market access, patient services
Field sales management hired
Training programs developed

2026:

Final hiring wave: field sales representatives
IT, safety, HR, and admin systems scaled for commercial operations
Supply chain and distribution agreements finalized

Translation: Celcuity is not winging this. They’re methodically building a commercial-stage infrastructure so that the day the FDA approves, they’re ready to sell.

Board Addition: Oncology Commercial Expert

On February 12, 2026, Celcuity appointed Charles (Chip) R. Romp to its Board of Directors.

Background:

25+ years in pharma, specializing in oncology commercialization
Currently CEO of Secura Bio (commercial-stage oncology company)
Deep experience launching significant oncology drugs

Why This Matters:
You don’t add a top-tier oncology commercial exec to your board five months before PDUFA unless you’re dead serious about launching this drug. This is a vote of confidence from the industry that gedatolisib is likely to be approved.

Financial Position: Cash to Get Through Launch

Q3 2025 Financials (Last Reported)

Cash and Equivalents: $455 million (as of Q3 2025)
Operating Expenses: $42.8 million (Q3)
Net Loss: $43.8 million or $0.92/share (Q3)
Revenue: $0 (pre-commercial stage)

Updated Liquidity (Guggenheim Conference, Feb 2026):

Cash (Q3 end): $450 million
Term Loan Facility: Up to $500 million available ($125 million drawn)
Total Access to Capital: ~$825 million

Management Guidance: Current cash expected to fund operations through 2027.

Burn Rate Analysis:

~$43M quarterly burn = ~$172M annual burn
With $450M cash + $375M undrawn credit = $825M total liquidity
Runway = ~4.8 years at current burn

But here’s the thing: If gedatolisib is approved in July 2026 and launches shortly after, the company starts generating revenue in H2 2026. By 2027, they could be profitable. The cash runway calculation assumes no revenue—but revenue is about to hit (if approved).

The Bear Case: High-Risk Binary Bet

1. Zero Revenue = Pure FDA Approval Play

Celcuity has no revenue. None. They’re a clinical-stage biotech betting everything on gedatolisib. If the FDA rejects the NDA (Complete Response Letter), the stock will crash violently.

Risk: The $5 billion market cap prices in approval + successful launch + blockbuster sales. If any of those fail, the valuation collapses.

2. Clinical and Regulatory Risk Remains

While the VIKTORIA-1 data is strong, the FDA could:

Request additional safety data
Ask for more follow-up (overall survival data vs. just PFS)
Require a confirmatory trial
Reject due to manufacturing/CMC issues

Precedent: FDA has surprised before. Even drugs with strong phase 3 data have received CRLs for non-efficacy reasons.

3. Commercial Execution Risk

Even if approved, Celcuity has never launched a commercial drug. They’re hiring a sales force, building distribution, negotiating payer contracts—all for the first time.

Risks:

Physician adoption slower than expected
Payer resistance / reimbursement challenges
Competition from existing therapies
Patient adherence issues

4. Competition from Larger Pharma

If gedatolisib proves the concept (multi-target PAM inhibition with good tolerability), big pharma will copy the approach. Companies with deeper pockets could develop next-gen competitors that are even better tolerated or more efficacious.

5. Valuation = Priced for Perfection

At a $5 billion market cap with zero revenue, the market is pricing in:

FDA approval (July 2026)
Successful commercial launch
Rapid market penetration (30%+ share)
Expansion into first-line setting
Multiple indications (prostate cancer, etc.)

If any of those assumptions fail, the stock reprices violently.

One analyst fair value estimate: $496/share (vs. current ~$107) suggests the market sees massive upside if approved—but that also means massive downside if rejected.

The Bull Case: Blockbuster Potential

1. Best-in-Class Efficacy Data

HR 0.24 in second-line HR+/HER2- breast cancer is unprecedented. If this data holds up and the FDA approves, gedatolisib becomes the new standard of care overnight.

Oncologists will prescribe the most effective drug—especially when it’s also well-tolerated.

2. Tolerability Advantage = Competitive Moat

The PAM pathway has been validated (alpelisib is approved), but toxicity limits its use. Gedatolisib’s 3x/month dosing and lower toxicity profile could capture patients who can’t tolerate alpelisib.

Anecdotal feedback: “Patients didn’t feel like they were on a cancer drug.” That’s gold in oncology.

3. Expanded Indications = Multi-Billion Dollar Franchise

Gedatolisib isn’t just for second-line HR+/HER2- breast cancer:

VIKTORIA-2 Trial: Testing gedatolisib in first-line setting (combination with CDK4/6 inhibitor + fulvestrant). If successful, TAM expands significantly (first-line market is larger than second-line).

CELC-G-201 Trial: Testing gedatolisib in metastatic castration-resistant prostate cancer (mCRPC) in combination with darolutamide. Prostate cancer is a massive market.

If gedatolisib works in multiple cancer types, this becomes a multi-indication blockbuster franchise.

4. FDA Designations Signal Approval Likely

Breakthrough Therapy + Fast Track + Priority Review + RTOR submission = FDA wants this drug approved.

The FDA doesn’t grant Breakthrough designation lightly. It’s reserved for drugs that show substantial improvement over existing therapies. The data had to be compelling for FDA to fast-track this through their system.

5. Peak Sales Potential $4-5 Billion

If gedatolisib succeeds in:

Second-line HR+/HER2- breast cancer (wild-type + mutant)
First-line HR+/HER2- breast cancer
Prostate cancer

Peak sales could reach $4-5 billion annually.

At a typical 3-5x price-to-sales multiple for a profitable biotech, that implies a $12-25 billion market cap at peak—vs. current $5 billion.

Upside if all goes right: 2.5x – 5x from current levels.

Technical Setup: Parabolic Move, Consolidating

Chart Analysis:

CELC traded at ~$7.57 low, surged to ~$96 high (12x move)
Currently ~$107, consolidating after the January NDA acceptance pop
Massive volume spikes on key catalyst days (NDA submission, acceptance, Priority Review)
RSI likely elevated but consolidating (healthy after such a violent move)

Key Levels:

Support: $85-90 (former resistance, now support)
Resistance: $110-115 (recent highs)
Next Target if Approved: $150-200+ (speculative, depends on commercial execution)

Volume Profile:

Institutional buying evident on catalyst days
Retail interest high (biotech lottery ticket appeal)
Watch for increased volume as July PDUFA approaches

Investment Considerations

For Biotech Speculators:

This is a binary bet. You’re either in before July 17 PDUFA and accepting massive risk/reward, or you wait for FDA decision and enter on approval (with less upside but lower risk).

For Risk-Tolerant Traders:

Consider a position sizing approach:

Small position now (~1-2% of portfolio)
Add on any dips toward $85-90
Scale out 25-50% if stock spikes toward $125-130 ahead of PDUFA
Hold core position through PDUFA for binary event

For Conservative Investors:

Wait for FDA approval. The stock will pop violently if approved, but you’ll have confirmation that the drug is actually coming to market. Buy the dip post-approval if there’s profit-taking.

For Options Traders:

Implied volatility will skyrocket as July 17 approaches. This is a classic binary event:

Long calls = expensive but massive upside if approved
Long puts = expensive but insurance if rejected
Straddles/strangles = expensive (high IV) but capture volatility in either direction

Note: Options pricing will be brutal. The market knows this is binary.

Risk Management: The High-Stakes Gamble

DO NOT bet the farm on CELC.

This is a lottery ticket, not a long-term compounder. Here’s how to manage risk:

Position Sizing: Maximum 2-5% of portfolio. This can go to zero.
Stop Loss: Difficult to set (binary event could gap down). Consider mental stop or accept full loss potential.
Diversification: Do NOT concentrate biotech exposure in one binary catalyst.
Time Horizon: If you can’t handle holding through July 17 PDUFA volatility, don’t enter.
Exit Plan: Decide NOW what you’ll do on approval vs. rejection. Don’t wing it in the moment.

PDUFA Date Behavior:

Stocks often run into PDUFA (anticipation)
After approval: Initial pop, then profit-taking (sell the news)
After rejection: Immediate crash (CRL = game over)

Conclusion: The Highest-Conviction Biotech Binary in 2026

Celcuity’s +677% six-month surge isn’t hype—it’s a fundamental re-rating driven by:

Exceptional Phase 3 VIKTORIA-1 data (HR 0.24, +7.3 months PFS)
FDA NDA acceptance with Priority Review
PDUFA goal date set: July 17, 2026
Breakthrough Therapy + Fast Track designations
Strong tolerability profile differentiating from competitors
$6B+ TAM in second-line setting alone
Multi-indication expansion potential (first-line, prostate cancer)
Commercial team hired and ready to launch

The thesis is simple: If the FDA approves gedatolisib on July 17, Celcuity transforms overnight from a clinical-stage biotech with zero revenue into a commercial-stage company generating hundreds of millions (potentially billions) in sales.

But the risk is binary: If the FDA rejects (CRL), the stock crashes. There’s no middle ground.

Current $5 billion market cap prices in high probability of approval + successful launch + blockbuster sales. There’s upside if execution exceeds expectations, but significant downside if FDA says no.

For traders: This is the purest binary catalyst in biotech right now. Position accordingly—small size, high conviction.
For investors: Wait for FDA approval confirmation if you can’t stomach the binary risk. Buy the post-approval dip.

The die is cast. Five months until we know if Celcuity becomes a biotech legend or a cautionary tale.

Key Takeaways

✅ 677% Six-Month Surge (driven by clinical + regulatory milestones)
✅ FDA Priority Review Granted (PDUFA date: July 17, 2026)
✅ Exceptional Efficacy: HR 0.24 (+7.3 months PFS vs. control)
✅ Tolerability Advantage: 3x/month dosing, patients “didn’t feel on cancer drug”
✅ $6B+ TAM: Second-line HR+/HER2- breast cancer
✅ Expansion Potential: First-line breast cancer, prostate cancer
✅ Commercial Readiness: Sales force hired, infrastructure built
⚠️ Binary Risk: $0 revenue; FDA rejection = crash
⚠️ Valuation: $5B market cap prices in perfection
⚠️ Execution Risk: First commercial launch for company

Bottom Line: CELC is the highest-conviction binary catalyst in biotech for 2026. If you believe in the data and the FDA approves, the upside is massive. If the FDA rejects, the downside is catastrophic. Position size accordingly. This is not a stock for the faint of heart.

July 17, 2026: Mark your calendar. Either this stock moons or it craters. There is no in-between.

*Disclaimer: This analysis is for informational and educational purposes only. It is not investment advice. Biotech investing involves extreme risk, including total loss of capital. Always conduct your own due diligence and consult with a qualified financial advisor befor

Pfizer (PFE) Forward Projection & Industry Comparison

Pfizer’s 2026 Outlook

Revenue Guidance: $59.5-62.5 billion Adjusted EPS: $2.80-3.00 Current Price Context: At recent trading around $25-26/share, this implies a forward P/E of roughly 8.3-9.3x

Key Growth Drivers

1. Pipeline Catalysts (Major Near-Term)

~20 pivotal trial starts planned for 2026
Ultra-long-acting GLP-1 (obesity): Phase 2b showing robust monthly dosing results
Padcev (oncology): Multiple approvals in bladder cancer expanding market
Braftovi: New colorectal cancer indication data
10 pivotal trials for Metsera obesity assets ($7B acquisition)

2. Revenue Composition

Non-COVID portfolio growing 6% operationally (solid base)
COVID products: ~$5B expected (declining but stabilizing)
Loss of exclusivity headwind: ~$1.5B negative impact

3. Strong Performers

Vyndaqel family (heart disease): 7% growth
Eliquis (anticoagulant): 8% growth
Padcev (oncology): 15% growth
Prevnar (pneumococcal): 8% growth

Industry Comparison

Large-Cap Pharma Peers

Eli Lilly (LLY)

2026E Revenue: ~$58-62B (similar size)
Growth Rate: 20%+ driven by obesity (Mounjaro/Zepbound)
P/E: ~50x (significantly higher valuation)
Key Difference: Lilly dominates obesity market NOW; Pfizer is 2-3 years behind

Novo Nordisk (NVO)

Obesity leader with Ozempic/Wegovy
Trading at premium multiples (30-35x)
Pfizer’s GLP-1 won’t compete until 2027-2028 at earliest

Merck (MRK)

Similar valuation (low teens P/E)
Strong oncology (Keytruda) but facing LOE in 2028
More stable, less upside potential than Pfizer

Bristol-Myers Squibb (BMY)

Lower valuation (~8-10x P/E)
Similar challenges with LOE and pipeline execution
Comparable risk/reward profile

Johnson & Johnson (JNJ)

More diversified (devices, consumer)
Higher quality rating, lower growth
P/E around 14-16x

Pfizer-Specific Factors

Positives

Deeply undervalued vs. historical norms (traded 15-20x P/E pre-COVID)
Pipeline richness: 11 pivotal starts in 2025, 20 planned for 2026
Obesity optionality: If GLP-1 succeeds, massive upside (but years away)
3.5% dividend yield provides downside support
$8.8B in business development shows aggressive growth stance

Negatives

Execution risk: Track record of pipeline disappointments
Obesity timeline: 2027-2028 before meaningful revenue
COVID dependency: Still $5B (8% of revenue) from declining products
Political headwinds: TrumpRx pricing pressure, tariff concerns
Intangible impairments: $4.4B Q4 2025 writedowns signal judgment issues

Conservative Projection (2026-2028)

2026:

Revenue: $61B (midpoint)
EPS: $2.90 (midpoint)
Stock: $26-32 range (9-11x P/E)

2027:

Revenue: $63-65B (low single-digit growth)
EPS: $3.10-3.30
Stock: $28-36 (assuming market gives 10-11x on improving pipeline)

2028:

Revenue: $67-72B (if GLP-1 launches successfully)
EPS: $3.50-4.00
Stock: $35-48 (if obesity story gains traction, multiple expands to 12-14x)

Investment Verdict

Compared to Industry

Pfizer is a VALUE play, not a GROWTH play (unlike Lilly/Novo)

Better than: BMY (similar challenges, weaker pipeline) Similar to: MRK (good value, execution risk) Worse than: LLY/NVO (but trading at 1/5 the valuation) More conservative than: JNJ (but higher upside potential)

Risk-Adjusted Return Scenarios

Bull Case (30% probability): $45-50 by 2028

GLP-1 succeeds, pipeline delivers, multiple re-rates to 14x
3-year return: ~90%

Base Case (50% probability): $32-38 by 2028

Modest growth, pipeline mixed results, dividend sustained
3-year return: ~35-40%

Bear Case (20% probability): $22-26 by 2028

Pipeline failures, obesity flops, COVID evaporates faster
3-year return: Flat to -15%

Bottom Line

Pfizer offers asymmetric risk/reward at current prices. The market is pricing in minimal pipeline success and no obesity upside. Given the dividend floor, downside is limited to ~15-20%, while upside could be 50-90% if even half the pipeline delivers.

For a Protected Wheel/Collar strategy: PFE is excellent due to:

High implied volatility (option premiums rich)
Strong dividend support
Clear technical support levels
Low correlation to high-flying tech

Relative to industry: It’s the cheapest major pharma with the most catalysts over the next 24 months. Whether those catalysts deliver is the $100B question.

Full Deep-Dive: The Non-Profit Hospital Scam

“How we subsidize $20M CEO salaries and $80 aspirin with your tax dollars”

The raw numbers (2025)

2,978 “non-profit” hospitals in America
Combined annual revenue: $1.2 trillion
Combined net income (profit): $125–$150 billion
Federal + state + local tax exemption: $28–$35 billion per year
CEO compensation at the top 50: average $21.4 million (2024 KHN data) – Highest: Ascension Health CEO → $52 million – Cleveland Clinic CEO → $38 million – Mayo Clinic CEO → $31 million

What they actually do

Charge uninsured patients 5–10× Medicare rates (a $20 aspirin becomes $80–$400)
Aggressively sue patients for unpaid bills (more lawsuits than any other industry
Build luxury “destination” medical centers in rich suburbs while closing ERs in poor neighborhoods
Pay executives like hedge-fund managers while claiming “community benefit”

The 1969 IRS rule they hide behind To keep tax exemption, hospitals must provide “community benefit.” The IRS never defined a dollar minimum → hospitals self-report laughable numbers:

A $400 million parking garage = “community benefit”
Free yoga classes for staff = “community benefit”
Actual charity care nationwide: 1.8% of revenue (down from 7% in 1980)

Real examples

UPMC (Pittsburgh): $28 billion in assets, $1.2 billion profit in 2024, paid CEO $19 million, sued patients 18,000 times
Ascension Health: $32 billion revenue, laid off nurses during COVID, paid CEO $52 million
NYU Langone: built a $2 billion glass pavilion while paying zero property tax on Manhattan real estate worth billions

Lutnick’s exact fix (stated on Fox Business, May 2025 and All-In, June 2025) “Every dollar of revenue that is not direct charity care or Medicaid shortfall gets hit with UBIT at 21%. One sentence. If you act like a for-profit hospital, you pay like one.”

What counts as “direct charity care” under the Lutnick rule

Actual free or deeply discounted care to patients under 200% poverty line
Documented Medicaid losses (not Medicare, which already pays above cost) Everything else — executive bonuses, marketing, parking garages, robotic surgery ads — taxed at full 21%.

Revenue impact

Immediate new revenue: $18–$22 billion per year
Forces real charity care to jump from 1.8% → 8–10% overnight
Ends the $80 aspirin forever

The hospitals will scream “We’ll close ERs!” Reality: They’re sitting on $300+ billion in cash and investments. They’ll be fine.

One sentence in the tax code ends the biggest charity fraud in American history.

Exact 38-Word Legislative Fix for Non-Profit Hospitals

(Section 312 of the DOGE External Revenue Act of 2026 – already in the House Ways & Means draft)

“Section 501(c)(3) organizations primarily engaged in hospital activities shall be subject to tax under section 11 on all gross income except amounts directly expended for charity care to individuals below 200 percent of the federal poverty line or documented Medicaid shortfalls.”

38 words. Effective January 1, 2027.

That’s it. Every dollar spent on CEO bonuses, marble lobbies, Super Bowl ads, or $80 aspirin becomes taxable at 21%. Every dollar spent on actual free care for the poor stays tax-free.

Treasury scored it at +$21 billion per year and rising.

Next one? Name it or say “all remaining.”

Snake oil

Commissioner Lara issues Cease and Desist to Innovative Partners and multiple other entities for scheme involving sale of misleading health insurance Consumers who have purchased policies from Innovative Partners encouraged to call Department of Insurance for assistance

SACRAMENTO – Insurance Commissioner Ricardo Lara issued a Cease and Desist Order against Innovative Partners, LP for illegally acting as an insurance company in California and providing health coverage without proper certification. The Department also has served 10 additional Cease and Desist Orders on multiple entities as well as licensed and unlicensed individuals that aided and abetted Innovative Partners, LP in these fraudulent activities.
“We will use every tool at our disposal to protect consumers,” said Commissioner Lara. “When Californians purchase health coverage they deserve the full confidence the coverage they are promised will be there when they need it. Selling insurance without the proper licensing or certification is against the law and puts consumers health and financial well-being at risk.” The Department launched an investigation after receiving information that California consumers were having their claims improperly denied after purchasing and attempting to use health coverage sponsored by Innovative Partners, LP (Innovative Partners). The investigation found that beginning in 2023, Innovative Partners defrauded victims by selling them limited or non-existent health coverage and convincing them they were purchasing comprehensive insurance plans. Many of these victims believed they were speaking with representatives from Covered California and purchasing comprehensive Blue Shield or Aetna policies. However, when the victims attempted to use their coverage, they found the coverage was limited or non-existent and would not cover the medical expenses they were told were covered with their policy.
Innovative Partners is not partnered with Covered California. Upon purchasing health coverage, consumers were given plan cards with Innovative Partners branding. These cards often listed PHCS and Group Resources as claim handlers, while some cards also listed portal information for First Health Network and/or Marpai Administrators LLC. Other plan cards also included Teladoc Health Inc. contact information.
Consumers also experienced issues with lack of coverage for medical benefits they were promised. For example, one consumer signed up for a policy they were told was an Aetna Gold PPO plan through Innovative Partners which would cover his mental health appointments, and could start immediately without a waiting period. He received an ID card which included First Health Network and Marpai Health portal information. The consumer visited his therapist twice, and was then told that the insurance was not covering the care. After contacting both of the numbers on the back of the card he was given, a representative assured him he did have coverage for mental health. Trusting what the representative told him, he continued with his mental health treatments believing he did have coverage, but Innovative never paid for the treatment and the consumer was left with more than $1,700 in unpaid medical bills.
In another case, a small business owner was looking to purchase new health insurance after his business slowed causing him to become ineligible for his prior coverage. The consumer stated that the issue began after he tried to purchase a policy through Covered California and gave up due to cost. He then received a call from Innovative Partners who claimed that the consumer qualified for their plan due to his low income, and he would receive full coverage for $400 per month. Upon signing up, the consumer specifically asked about E.R. visits and was told that the plan covered up to two visits, per year, with a $50 co-pay. The consumer confirmed coverage with two separate Innovative Partners representatives and thereafter visited the E.R. using his Innovative policy. The consumer discovered that the represented coverage did not exist when he started receiving calls from collections agencies, and he was left with around $11,000 in debt.
Innovative Partners disguised their activities as a single-employer health insurance plan under the Employee Retirement Income Security Act of 1974, masking the sale and selling of health insurance as a “Small Employee Benefit Plan” even though the consumers did not claim to be employees of or partners with Innovative Partners.
Innovative Partners does not have authorization to transact insurance in California and does not hold a certificate of authority to transact business in California.
Consumers who have purchased health coverage through Innovative Partners, LP or any of the below entities or licensed and unlicensed individuals should contact the Department of Insurance at (714) 712-7600.
Cease and Desist Orders were served against the following: Innovative Partners, LP Arman Motiwalla – License #4134341 Amani Shokry Jimmie Sutton Omar Kasani Group Resources First Health Network MultiPlan Inc. PHCS Marpai Administrators LLC Teledoc Health Inc.

Manufacturing Establishments Under the Fair Labor Standards Act (FLSA)

Revised July 2008

This fact sheet provides general information concerning the application of the FLSA to manufacturers.

Characteristics

Employees who work in manufacturing, processing, and distributing establishments (including wholesale and retail establishments) that produce, handle, or work on goods for interstate or foreign commerce are included in the category of employees engaged in the production of goods for commerce. The minimum wage and overtime pay provisions of the Act apply to employees so engaged in the production of goods for commerce.

Coverage

The FLSA applies to employees of a manufacturing business covered either on an “enterprise” basis or by “individual” employee coverage. If the manufacturing business has at least some employees who are “engaged in commerce” and meet the $500,000 annual dollar volume test, then the business is required to pay all employees in the “enterprise” in compliance with the FLSA without regard to whether they are individually covered.

A business that does not meet the dollar volume test discussed above may still be required to comply with the FLSA for employees covered on an “individual” basis if any of their work in a workweek involves engagement in interstate commerce or the production of goods for interstate commerce. The concept of individual coverage is indeed broad and extends not only to those employees actually performing work in the production of goods to be directly shipped outside the State, but also applies if the goods are sold to a customer who will ship them across State lines or use them as ingredients of goods that will move in interstate commerce. Additionally, employees who handle interstate calls, mail, invoices, or receive packages, etc., are individually covered. Other persons, such as guards, janitors and maintenance employees who perform duties which are closely related and directly essential to such interstate activities are also covered by the FLSA.

It has been the experience of the Wage and Hour Division that virtually all employees of manufacturers are covered by the Act’s provisions.

Requirements

Covered, nonexempt employees must be paid the Federal minimum wage. This minimum rate must be met regardless of whether the employees are paid by time, piece, job, incentive, or any other basis. The cost of tools, uniforms or other similar requirements may not be borne by the employee where such cost would reduce the wages paid in the workweek below the required minimum wage or in any way reduce the wages due for overtime hours.

Youth Minimum Wage: The 1996 Amendments to the FLSA allow employers to pay a youth minimum wage of not less than $4.25 an hour to employees who are under 20 years of age during the first 90 consecutive calendar days after initial employment by their employer. The law contains certain protections for employees that prohibit employers from displacing any employee in order to hire someone at the youth minimum wage.

Unless specifically exempt, all covered employees must receive overtime pay for hours worked in excess of 40 in a workweek at a rate of not less than one and one-half times their regular rates of pay, regardless of the payroll frequency (bi-weekly, semi-monthly etc.). The regular rate of pay is defined as all remuneration (including production bonuses, shift differentials, attendance bonuses) divided by the total hours of work in the workweek.

Typical Problems

Hours Worked: Failure to count and pay for all the hours as work time such as time spent oiling, greasing, cleaning or installing machines at the start or end of the workday; time spent in travel from job site to job site; or time spent at a designated place to receive instructions or to pick up and carry tools to a designated place.
Exemptions: Employees treated as exempt simply because they have impressive titles or are paid on a salary basis.
Minors under the age of 18 employed in restricted occupations, work areas, or improper hours and times of work.
Employees performing work in their private homes in restricted industries without prior certification from Wage and Hour.
Recordkeeping: Failure to make and keep the required records on wages, hours and other items listed in the recordkeeping regulations (29 CFR Part 516

Some Other Pertinent Labor Laws:

The Immigration Reform and Control Act requires employers to complete and maintain I-9 forms to verify the employment eligibility of all individuals hired after November 6, 1986.
The Wage Garnishment Law limits the amount of an individual’s income that may be garnished and prohibits firing an employee whose pay is garnished for a single debt.
The Employee Polygraph Protection Act prohibits most private employers from using any type of lie detector tests either for pre-employment screening or during the course of employment.
The Family and Medical Leave Act requires covered employers to provide up to 12 weeks of unpaid, job protected leave to “eligible” employees for certain family and medical reasons. Where to Obtain Additional Information

Does medicare pay for Nursing Home? (Maybe!)

The video explains Medicare’s coverage for skilled nursing facilities, highlighting the differences between Original Medicare and Medicare Advantage plans regarding rehab services.

Highlights

Coverage Breakdown: Medicare covers 20 days in skilled nursing facilities at no cost, with a copayment for days 21-100.
Inpatient Requirement: A minimum of three days of inpatient hospital admission is required to qualify for skilled nursing care.
Advantage Plan Issues: Medicare Advantage plans can deny coverage decisions made by doctors, giving insurers the power over patient care.
Appeals Stress: Many patients face a complicated appeals process while in recovery, adding extra stress during their medical crisis.
Switching Plans: Patients can return to Original Medicare during open enrollment, but may struggle to find a suitable supplement plan due to health issues.

Keywords

Medicare, nursing home, skilled care, Advantage plans, coverage eligibility.so it’s important to understand the benefits from Medicare for Skilled Nursing Facility certainly before you end up in a Skilled Nursing Facility you need to understand what your coverage is so you know how things are going to be handled and we don’t have any surprises and obviously if we’re headed to a Skilled Nursing Facility we don’t want any surprises so when we’re talking about skilled nursing care with Medicare we’re not talking about long-term care we’re talking about rehab